Form 4: Neal C. Bradsher Reports Stock Option Grant and Disposal at Lineage Cell Therapeutics

Director Neal C. Bradsher reports the acquisition and disposal of options to purchase common shares of Lineage Cell Therapeutics.

Summary

• On July 1, 2024, Neal C. Bradsher, a director and 10% owner of Lineage Cell Therapeutics, Inc. (LCTX), reported transactions involving derivative securities.
• Bradsher was granted options to purchase 75,000 common shares at $0.9541 per share, which will vest on July 1, 2025, contingent on continued board membership.
• These options were granted as director compensation under the company's 2021 Equity Incentive Plan.
• Bradsher also reported the disposal of options to purchase 50,000 common shares at $1.41, 50,000 common shares at $1.57, 50,000 common shares at $2.86, 40,000 common shares at $0.8263 and 40,000 common shares at $1.03.
• Bradsher directly owns options to purchase 255,000 common shares after the reported transactions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option transactions. There is no inherent positive or negative implication.

Positives

• The grant of options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.

Stakeholder Impact

• Shareholders are informed about the director's stock ownership and alignment of interests.
• Employees may be indirectly affected by the director's incentives to improve company performance.

Key Dates